An Expanded Access Study of T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.
Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.
This analysis was not as stringent as a conventional clinical trial, Yardley says, and aimed to evaluate patients treated with T-DM1 in the community setting. In this trial, patients received a median of 8 prior therapies and were able to receive T-DM1 before its FDA approval.
Clinical Pearls
The time from initial metastatic diagnosis to receiving T-DM1 in this trial was a mean of 42 months, Yardley says, which is astounding and highlights the benefit of HER2-targeted therapies. Among patients who remained on T-DM1 for over a year, median time from diagnosis to T-DM1 was 60 months. This as well reinforces the advancements of HER2-targeted therapies, Yardley says.
- This trial looked at T-DM1 in the community setting of patients
- The patient population received a median of 8 prior therapies for HER2+ metastatic disease
- Safety profile and activity were similar to previous conventional clinical trials
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
